PMID- 33552261
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210210
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 21
IP  - 2
DP  - 2021 Feb
TI  - Impact of chromosome 17 centromere copy number increase on patient survival and 
      human epidermal growth factor receptor 2 expression in gastric adenocarcinoma.
PG  - 142
LID - 10.3892/ol.2020.12403 [doi]
LID - 142
AB  - The accurate evaluation of human epidermal growth factor receptor 2 (HER2) status 
      is essential for the appropriate use of targeted therapies. An increased number 
      of chromosome 17 centromere enumeration probe (CEP17) signals may underrate 
      fluorescence in situ hybridization (FISH) outcomes, resulting in false-negative 
      or a false-equivocal HER2 status assessment. The aim of the present study was to 
      assess the frequency of CEP17 copy number increase (CNI), its effects on HER2 
      protein expression (and the subsequent effects on tumor cells), and the survival 
      outcomes of patients with gastric cancer. Archival primary tumor samples from 244 
      patients that underwent gastric resection for adenocarcinoma were retrieved for 
      both HER2 protein expression analysis (using immunochemistry) and HER2 gene 
      amplification (using FISH). The associations between HER2 status, CEP17 CNI and 
      multiple clinicopathological parameters (including survival outcome), were 
      assessed. The relationship between CEP17 CNI and HER2 protein upregulation was 
      also investigated. CEP17 CNI was detected in 17.2% of cases, and a strong 
      association between CEP17 CNI and HER2 upregulation was revealed. The impact of 
      CEP17 CNI on survival did not reach statistical significance. Consequently, CEP17 
      CNI was discovered to be strongly associated with HER2 upregulation in tumor 
      cells, which may characterize a critical issue in HER2 testing. Therefore, the 
      eligibility for HER2-targeted agents in CEP17 CNI-positive patients warrants 
      further recognition.
CI  - Copyright: (c) Ciesielski et al.
FAU - Ciesielski, Maciej
AU  - Ciesielski M
AD  - Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian 
      Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland.
AD  - Division of Propedeutics of Oncology, Medical University of Gdansk, Gdansk, 
      Pomeranian Voivodship 80-210, Poland.
FAU - Szajewski, Mariusz
AU  - Szajewski M
AD  - Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian 
      Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland.
AD  - Division of Propedeutics of Oncology, Medical University of Gdansk, Gdansk, 
      Pomeranian Voivodship 80-210, Poland.
FAU - Walczak, Jakub
AU  - Walczak J
AD  - Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian 
      Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland.
FAU - Peksa, Rafal
AU  - Peksa R
AD  - Department of Pathomorphology, Medical University of Gdansk, Gdansk, Pomeranian 
      Voivodship 80-210, Poland.
FAU - Lenckowski, Radoslaw
AU  - Lenckowski R
AD  - Department of Pathomorphology, Gdynia Centre of Oncology, Pomeranian Hospitals, 
      Gdynia, Pomeranian Voivodship 81-519, Poland.
FAU - Supel, Malgorzata
AU  - Supel M
AD  - Department of Pathomorphology, Gdynia Centre of Oncology, Pomeranian Hospitals, 
      Gdynia, Pomeranian Voivodship 81-519, Poland.
FAU - Zielinski, Jacek
AU  - Zielinski J
AD  - Department of Oncological Surgery, Medical University of Gdansk, Gdansk, 
      Pomeranian Voivodship 80-210, Poland.
FAU - Kruszewski, Wieslaw Janusz
AU  - Kruszewski WJ
AD  - Department of Oncological Surgery, Gdynia Centre of Oncology, Pomeranian 
      Hospitals, Gdynia, Pomeranian Voivodship 81-519, Poland.
AD  - Division of Propedeutics of Oncology, Medical University of Gdansk, Gdansk, 
      Pomeranian Voivodship 80-210, Poland.
LA  - eng
PT  - Journal Article
DEP - 20201221
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC7798021
OTO - NOTNLM
OT  - erbB-2
OT  - fluorescence in situ hybridization
OT  - genes
OT  - human chromosome pair 17
OT  - stomach neoplasm
EDAT- 2021/02/09 06:00
MHDA- 2021/02/09 06:01
PMCR- 2020/12/21
CRDT- 2021/02/08 05:36
PHST- 2020/05/19 00:00 [received]
PHST- 2020/11/16 00:00 [accepted]
PHST- 2021/02/08 05:36 [entrez]
PHST- 2021/02/09 06:00 [pubmed]
PHST- 2021/02/09 06:01 [medline]
PHST- 2020/12/21 00:00 [pmc-release]
AID - OL-0-0-12403 [pii]
AID - 10.3892/ol.2020.12403 [doi]
PST - ppublish
SO  - Oncol Lett. 2021 Feb;21(2):142. doi: 10.3892/ol.2020.12403. Epub 2020 Dec 21.